Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Transfusion. 2021 Aug;61(8):2245-2249. doi: 10.1111/trf.16524. Epub 2021 May 27.
COVID-19 convalescent plasma (CCP) is plasma collected from individuals who have recovered from SARS-CoV-2 infection. The FDA Emergency Use Authorization restricts use of CCP to high-titer units only. The purpose of this study was to determine if donor ABO blood group was associated with SARS-CoV-2 antibody response, and subsequent qualification as high-titer CCP.
All CCP donations collected from April 21, 2020 to September 1, 2020 were included. The Abbott ARCHITECT semi-quantitative chemiluminescent microparticle immunoassay was used to assess IgG antibodies to the nucleocapsid protein of SARS-CoV-2. Units with a S/C value ≥4.5 were considered high titer.
A total of 232 CCP donations were evaluated. There were no significant differences in the distribution of sex, age, and interval from symptom resolution to donation by ABO blood group. The mean SARS-CoV-2 IgG antibody S/C value was significantly lower in blood group O donations (3.6), compared to blood group A (5.0) donations (p < .001). There was no difference in antibody response between the other blood group pairings. Blood group O donations resulted in a lower percentage of high-titer units (35%), compared to blood group A (60%), B (58%), and AB (65%) donations.
Blood group O donations were found to have significantly lower levels of SARS-CoV-2 IgG nucleocapsid antibodies compared to blood group A donations and were less likely to produce CCP units that qualified as high titer. These findings may aid donor recruitment to promote availability of high-titer CCP to meet patient needs.
COVID-19 恢复期血浆（CCP）是从已从 SARS-CoV-2 感染中康复的个体中采集的血浆。FDA 紧急使用授权将 CCP 的使用仅限于高滴度单位。本研究的目的是确定供体 ABO 血型是否与 SARS-CoV-2 抗体反应以及随后的高滴度 CCP 资格相关。
纳入 2020 年 4 月 21 日至 2020 年 9 月 1 日期间收集的所有 CCP 捐赠。使用 Abbott ARCHITECT 半定量化学发光微粒子免疫分析测定法评估针对 SARS-CoV-2 核衣壳蛋白的 IgG 抗体。S/C 值≥4.5 的单位被认为是高滴度。
共评估了 232 个 CCP 捐赠。ABO 血型的性别、年龄和从症状缓解到捐赠的间隔分布无显著差异。与血型 A（5.0）捐赠相比，血型 O（3.6）捐赠的 SARS-CoV-2 IgG 抗体 S/C 值明显较低（p<0.001）。其他血型配对之间的抗体反应没有差异。与血型 A（60%）、B（58%）和 AB（65%）捐赠相比，血型 O 捐赠的高滴度单位比例较低（35%）。
与血型 A 捐赠相比，血型 O 捐赠的 SARS-CoV-2 IgG 核衣壳抗体水平明显较低，并且不太可能产生符合高滴度标准的 CCP 单位。这些发现可能有助于招募供体，以增加高滴度 CCP 的可用性，以满足患者的需求。
